Heron Therapeutics Inc vs Opendoor Technologies Inc — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Opendoor Technologies Inc trades at $4.39 (market cap $4.29B). The key difference: Opendoor Technologies Inc is far larger — about 46.9× Heron Therapeutics Inc's market cap, and Opendoor Technologies Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | OPEN | |
|---|---|---|
Market Cap | $91.46M | $4.29B |
Sector | Health | Real Estate |
52-Week High | $1.96 | $10.52 |
52-Week Low | $0.39 | $1.84 |
Enterprise Value | $189.36M | $4.63B |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Opendoor Technologies (OPEN) trades at $4.415, down 1.89% on the day, reflecting ongoing market skepticism despite recent operational improvements. The stock shows a bearish technical trend with mixed oscillators, while fundamentals reveal persistent losses with a -35.25% net income margin and negative ROE of -173.61%. Revenue has declined from $15.6B in 2022 to $4.37B in 2025, though cash flow turned positive in 2025 at $538M. Recent news highlights CEO focus on housing market challenges and India operations closure to prioritize AI integration.
The outlook remains cautious with high debt and profitability concerns offset by low P/S valuation and analyst 'Hold' consensus. Key risks include interest rate sensitivity and execution of the Opendoor 2.0 model, while potential upside hinges on margin stabilization and seasonal housing rebounds. Investors face a high-risk, speculative opportunity amid structural shifts in real estate tech.
Trailing returns across standard periods
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →